Cibus (CBUS) Cash from Financing Activities (2017 - 2025)
Cibus (CBUS) posted Cash from Financing Activities of -$458000.0 for Q4 2025, up 36.83% sequentially from -$725000.0 in Q3 2025, and down 49.67% YoY from -$910051.9 in Q4 2024.
Cibus (CBUS) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Cibus has reported Cash from Financing Activities for 9 years, with the latest figure at -$458000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 49.67% year-over-year to -$458000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $46.6 million (up 14.9% YoY) and the FY2025 annual result came in at $46.6 million, up 14.9% from the prior year.
- Cash from Financing Activities climbed to -$458000.0 in Q4 2025 per CBUS's latest filing, from -$725000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $26.6 million in Q2 2025 and troughed at -$725000.0 in Q3 2025.
- A 5-year average of $6.1 million and a median of $511500.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 397.18% in 2022, then soared 19138.95% in 2023.
- Over 5 years, Cash from Financing Activities stood at $3.8 million in 2021, then sank by 97.49% to $95000.0 in 2022, then jumped by 19138.95% to $18.3 million in 2023, then tumbled by 101.67% to -$306000.0 in 2024, then sank by 49.67% to -$458000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$458000.0, -$725000.0, and $26.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -458,000.00 |
| Dec 31, 2025 | -458,000.00 |
| Sep 30, 2025 | -725,000.00 |
| Sep 30, 2025 | -725,000.00 |
| Jun 30, 2025 | 26.56 Mn |
| Jun 30, 2025 | 26.56 Mn |
| Mar 31, 2025 | 21.27 Mn |
| Mar 31, 2025 | 21.27 Mn |
| Dec 31, 2024 | -306,000.00 |
| Dec 31, 2024 | -306,000.00 |
| Sep 30, 2024 | 12.65 Mn |
| Sep 30, 2024 | 12.65 Mn |
| Jun 30, 2024 | 22.73 Mn |
| Jun 30, 2024 | 22.73 Mn |
| Mar 31, 2024 | 5.52 Mn |
| Mar 31, 2024 | 5.52 Mn |
| Dec 31, 2023 | 18.28 Mn |
| Dec 31, 2023 | 18.28 Mn |
| Sep 30, 2023 | -619,000.00 |
| Sep 30, 2023 | -619,000.00 |